'Dose regimen' diaporamas de présentation

Curis, Inc. (NASDAQ: CRIS) Corporate Presentation January 2006

Curis, Inc. (NASDAQ: CRIS) Corporate Presentation January 2006. Forward Looking Statements.

1.1k views • 44 slides

??????????????

??????????????. ??? ????????. Bridging. Climate Medical Practice Culture Regulatory practice GCP Drug-drug interaction. Extrinsic factors Intrinsic factors. Genetic. Gender. Race. Renal Disease. Hepatic Disease. Age. Which way ?. ???????. ICH E5

631 views • 42 slides

??????????????

??????????????. ??? ????????. Bridging. Climate Medical Practice Culture Regulatory practice GCP Drug-drug interaction. Extrinsic factors Intrinsic factors. Genetic. Gender. Race. Renal Disease. Hepatic Disease. Age. Which way ?. ???????. ICH E5

423 views • 42 slides

Bayesian Adaptive Methods

Bayesian Adaptive Methods. Carrie Deis Nadine Dewdney. Overview. Phase I clinical trials Standard Designs Adaptive Designs Bayesian Approach Traditional vs. Bayesian Hybridization FDA Guidance Conclusion. Phase I . Conducted to determine toxicity for the dosing of the new intervention

763 views • 27 slides

Ibogaine Therapy: Forms and Dose Regimens

373 views • 23 slides

OPTIMUS

OPTIMUS. Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients with Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study.

368 views • 11 slides

Case Studies in Modeling and Simulation

Case Studies in Modeling and Simulation. Discussion Stella G. Machado, Ph.D. Office of Biostatistics/OTS/CDER/FDA FDA/Industry Workshop, September 2006. Regulatory issue. Approval was sought for monotherapy for pediatric population, without another clinical trial

292 views • 9 slides